Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Dec 31, 2013

Filed with the SEC on Feb 14, 2014 and accepted by EDGAR at Feb 14, 2014, 16:24 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-10-01 to 2013-12-31$17.5kus-gaap:Revenues
Revenue9 months2013-04-01 to 2013-12-31$2.3mus-gaap:Revenues
Cost of revenue3 months2013-10-01 to 2013-12-31$7.8kus-gaap:CostOfRevenue
Cost of revenue9 months2013-04-01 to 2013-12-31$1.9mus-gaap:CostOfRevenue
Selling, general and administrative3 months2013-10-01 to 2013-12-31$156.0kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2013-04-01 to 2013-12-31$930.1kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2013-10-01 to 2013-12-31−$294.0kus-gaap:OperatingIncomeLoss
Operating income9 months2013-04-01 to 2013-12-31−$987.5kus-gaap:OperatingIncomeLoss
Interest expense3 months2013-10-01 to 2013-12-31$52.5kus-gaap:InterestExpense
Interest expense9 months2013-04-01 to 2013-12-31$233.5kus-gaap:InterestExpense
Income tax3 months2013-10-01 to 2013-12-31$1.9kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2013-04-01 to 2013-12-31$5.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-10-01 to 2013-12-31−$310.5kus-gaap:NetIncomeLoss
Net income9 months2013-04-01 to 2013-12-31−$1.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2013-10-01 to 2013-12-31−$0.04us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2013-04-01 to 2013-12-31−$0.20us-gaap:EarningsPerShareDiluted
Basic EPS3 months2013-10-01 to 2013-12-31−$0.04us-gaap:EarningsPerShareBasic
Basic EPS9 months2013-04-01 to 2013-12-31−$0.20us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2013-10-01 to 2013-12-317,734,444 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2013-04-01 to 2013-12-317,734,444 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2013-04-01 to 2013-12-31−$866.9kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-12-31$440.6kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-12-31$3.8mus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$18.2mus-gaap:Assets
Current liabilitiesAt period end2013-12-31$3.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-12-31$3.9mus-gaap:Liabilities
Shareholders' equityAt period end2013-12-31$13.7mus-gaap:StockholdersEquity
Shares outstandingAt period end2013-12-317,980,919 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001185185-14-000346. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.